Ai Nose was Ainos’s largest revenue line in fiscal 2025, bringing in $370.08K of $372.47K (99%).
| Related and Nonrelated Parties | FY 2024 | FY 2025 |
|---|---|---|
| Ai Nose | — | $370.08K |
| Pet Supplements | $60.96K | $2.39K |
| Antigen Rapid Test Kits | $1.22K | — |
| Total | $62.19K | $372.47K |
Ainos brought in $372.47K from its two revenue lines in fiscal 2025, the year ended December 31, 2025. Ainos regrouped these revenue lines after fiscal 2024, so the total does not compare directly with that year's $62.19K. Ai Nose was the largest at $370.08K (99.4%), ahead of Pet Supplements at $2.39K (0.6%).
Ainos began breaking out Ai Nose in fiscal 2025, when it brought in $370.08K. Ainos stopped reporting Antigen Rapid Test Kits as a separate revenue line after fiscal 2024, when it brought in $1.22K.
Ainos (AIMD) reports its revenue by related and nonrelated parties. In fiscal 2025, Ai Nose was its largest revenue line, bringing in $370.08K (99.4% of the total), followed by Pet Supplements at $2.39K (0.6%).
Ai Nose was Ainos' largest revenue line in fiscal 2025, bringing in $370.08K, or 99.4% of the $372.47K total across its two revenue lines.
Every figure comes from Ainos' annual financial filings, as reported. Each line keeps the name Ainos gives it, and years follow its fiscal calendar.
Ainos' revenue by related and nonrelated parties goes back to fiscal 2024, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.